Who are Quadrivalent High-dose Influenza Vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): VaxigripTetra™ by Sanofi, Inc., Hualan TIV, Fluzone® (IM), Flublok™ Quadrivalent by Sanofi, Inc., Trivalent split Inf, SP Shz TIV.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/quadrivalent-high-dose-influenza-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Quadrivalent High-dose Influenza Vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Quadrivalent High-dose Influenza Vaccine (Quadrivalent High-dose Influenza Vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Influenza vaccine. Area: Immunology.

phase 3 Influenza vaccine Immunology Biologic Live · refreshed every 30 min

Target snapshot

Quadrivalent High-dose Influenza Vaccine (Quadrivalent High-dose Influenza Vaccine) — Janssen Vaccines & Prevention B.V.. This vaccine induces an immune response against multiple influenza strains.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Quadrivalent High-dose Influenza Vaccine TARGET	Quadrivalent High-dose Influenza Vaccine	Janssen Vaccines & Prevention B.V.	phase 3	Influenza vaccine
VaxigripTetra™ by Sanofi, Inc.	VaxigripTetra™ by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Inactivated quadrivalent influenza vaccine
Hualan TIV	Hualan TIV	Sanofi	marketed	Inactivated influenza vaccine
Fluzone® (IM)	Fluzone® (IM)	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	inactivated influenza vaccine
Flublok™ Quadrivalent by Sanofi, Inc.	Flublok™ Quadrivalent by Sanofi, Inc.	Centers for Disease Control and Prevention	marketed	Recombinant inactivated influenza vaccine	Influenza hemagglutinin (HA) protein
Trivalent split Inf	Trivalent split Inf	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Inactivated influenza vaccine
SP Shz TIV	SP Shz TIV	Sanofi	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Influenza vaccine class)

GlaxoSmithKline · 8 drugs in this class
Sanofi Pasteur, a Sanofi Company · 2 drugs in this class
Seqirus · 2 drugs in this class
MedImmune LLC · 1 drug in this class
AstraZeneca · 1 drug in this class
Novartis · 1 drug in this class
Protein Sciences Corporation · 1 drug in this class
ModernaTX, Inc. · 1 drug in this class
Institute of Vaccines and Medical Biologicals, Vietnam · 1 drug in this class
Janssen Vaccines & Prevention B.V. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Quadrivalent High-dose Influenza Vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/quadrivalent-high-dose-influenza-vaccine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab